Systemic Therapy for Prostate Cancer

EP: 1.Incidence and Risk Factors of Prostate Cancer

EP: 2.Presentation and Diagnosis of Prostate Cancer

EP: 3.Screening and Diagnosis of Prostate Cancer

EP: 4.Prostate Cancer Prognosis and Risk Stratification

EP: 5.Differences in the Treatment of Patients with Prostate Cancer

EP: 6.Prostate Cancer: Treatment Decision-Making and the Role of Guidelines

EP: 7.Informing Prostate Cancer Treatment Decisions with Clinical Trials and Real-World Evidence

Now Viewing

EP: 8.Systemic Therapy for Prostate Cancer

EP: 9.Androgen Deprivation Therapy for Prostate Cancer

EP: 10.Metastatic Hormone-Sensitive Prostate Cancer Treatment Options

EP: 11.Overview of Castrate-Resistant Prostate Cancer (CRPC)

EP: 12.Treatment Options for Nonmetastatic CRPC

EP: 13.Treatment Approach for Patients With Metastatic CRPC

EP: 14.The Role of Combination Therapy in mCRPC

EP: 15.Improving Clinical Trials in Prostate Cancer

EP: 16.Educating Patients and Caregivers About Prostate Cancer

EP: 17.Advice for Patients With Prostate Cancer

This is a synopsis of an Educated Patient Sound Bites series featuring Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute; Rashid K. Sayyid, MD, MSc, of the University of Toronto; and Reginald Tucker-Seeley, MA, ScM, ScD, of ZERO Prostate Cancer.

Dr Rashid K. Sayyid discusses chemotherapy options docetaxel and cabazitaxel, which stabilize microtubules to inhibit cancer cell proliferation. He then covers immunotherapy with programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors, which prevent cancer cells from tricking the immune system.

The most commonly used treatment is androgen deprivation therapy, including luteinizing hormone-releasing hormone (LHRH) agonists to reduce testosterone production and gonadotropin-releasing hormone (GnRH) antagonists to immediately inhibit testosterone. Newer drugs also prevent adrenal testosterone production. Dr Sayyid explains testosterone promotes prostate cancer growth, so limiting levels fights proliferation.

Additional drug classes are then summarized, including sipuleucel-T immunotherapy whereby peripheral blood cells activate against antigens then reinject to target cancer, radium Ra 223 dichloride which emits alpha radiation to damage cancer cell DNA, and PARP inhibitors like olaparib, rucaparib, and talazoparib that prevent DNA damage repair prompting cancer cell death.

In total, Dr. Rashid K. Sayyid overviews major drug categories for treating prostate cancer - chemotherapy, immunotherapy, hormone therapy, therapeutic vaccines, alpha radiation, and PARP inhibitors.

*Video synopsis is AI-generated and reviewed by CURE editorial staff.